Publication: Real-Life Impact of Glucocorticoid Treatment in COVID-19 Mortality: A Multicenter Retrospective Study
Loading...
Author
Gómez Muñoz, Ana María
Fernández-Cruz, Ana
Lavilla Olleros, Cristina
Giner-Galvañ, Vicente
Ausín-García, Cristina
Wikman-Jorgensen, Philip Erick
Vargas, Juan A.
Rubio-Rivas, Manuel
Laureiro, Jaime
Fernández-Bermúdez, Daniel
Journal Title
Journal ISSN
Volume Title
Date
Citation
J Clin Med . 2021 Oct 13;10(20):4678
Conference
Publisher
MDPI
Abstract
We aimed to determine the impact of steroid use in COVID-19 in-hospital mortality, in a
retrospective cohort study of the SEMICOVID19 database of admitted patients with SARS-CoV-2
laboratory-confirmed pneumonia from 131 Spanish hospitals. Patients treated with corticosteroids
were compared to patients not treated with corticosteroids; and adjusted using a propensity-score
for steroid treatment. From March–July 2020, 5.262 (35.26%) were treated with corticosteroids and
9.659 (64.73%) were not. In-hospital mortality overall was 20.50%; it was higher in patients treated
with corticosteroids than in controls (28.5% versus 16.2%, OR 2.068 [95% confidence interval; 1.908
to 2.242]; p = 0.0001); however, when adjusting by occurrence of ARDS, mortality was significantly
lower in the steroid group (43.4% versus 57.6%; OR 0.564 [95% confidence interval; 0.503 to 0.633];
p = 0.0001). Moreover, the greater the respiratory failure, the greater the impact on mortality of
the steroid treatment. When adjusting these results including the propensity score as a covariate,
in-hospital mortality remained significantly lower in the steroid group (OR 0.774 [0.660 to 0.907],
p = 0.002). Steroid treatment reduced mortality by 24% relative to no steroid treatment (RRR 0.24).
These results support the use of glucocorticoids in COVID-19 in this subgroup of patients.
